ICML 2023 | OLYMPIA-5: odronextamab + lenalidomide for R/R indolent lymphoma
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses the ongoing OLYMPIA-5 study, a Phase III randomized trial investigating odronextamab plus lenalidomide for relapsed/refractory (R/R) indolent lymphoma. The combination treatment will be compared to the standard treatment of rituximab plus lenalidomide, as odronextamab has shown promising preliminary activity as a monotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
OLYMPIA-5 is an ongoing study just started a few months ago. OLYMPIA-5 is the Phase III randomized study for relapsed/refractory indolent lymphoma, including follicular lymphoma and also marginal zone lymphoma. OLYMPIA-5 is a randomization between bispecific antibodies, that is odronextamab plus lenalidomide compared to the standard rituximab-lenalidomide for a total of 12 cycles. This is based on the preliminary activity that has been shown with odronextamab as a single agent in indolent lymphoma, mostly in follicular lymphoma...
OLYMPIA-5 is an ongoing study just started a few months ago. OLYMPIA-5 is the Phase III randomized study for relapsed/refractory indolent lymphoma, including follicular lymphoma and also marginal zone lymphoma. OLYMPIA-5 is a randomization between bispecific antibodies, that is odronextamab plus lenalidomide compared to the standard rituximab-lenalidomide for a total of 12 cycles. This is based on the preliminary activity that has been shown with odronextamab as a single agent in indolent lymphoma, mostly in follicular lymphoma. Odronextamab has really good activity in these cases of relapsed/refractory patients with an overall response rate of 82%, complete remission rate of 75%. But of course, we have to show the efficacy and the safety of the combination compared to a very well used combination that is Rituxan-lenalidomide in relapsed/refractory indolent lymphoma.
Read more...
